Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Thymoma × Everolimus × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 49 Carcinoma, Renal Cell 30 Neoplasm Metastasis 18 Neoplasms 15 Kidney Neoplasms 14 Neuroendocrine Tumors 11 Carcinoma, Neuroendocrine 9 Prostatic Neoplasms 7 Melanoma 7 Triple Negative Breast Neoplasms 6 Thyroid Neoplasms 6 Sarcoma 6 Meningioma 6 Lymphoma 6 Glioma 6 Endometrial Neoplasms 6 Tuberous Sclerosis 5 Stomach Neoplasms 5 Recurrence 5 Lymphoma, Mantle-Cell 5 Head and Neck Neoplasms 5 Colorectal Neoplasms 5 Carcinoma, Hepatocellular 5 Carcinoma 5 Pancreatic Neoplasms 4 Ovarian Neoplasms 4 Lymphoma, Large B-Cell, Diffuse 4 Liver Neoplasms 4 Carcinoma, Islet Cell 4 Astrocytoma 4

Interventions

Sunitinib 5 pembrolizumab 4 Paclitaxel 4 Carboplatin 4 Radiotherapy 3 Cyclophosphamide 3 Cisplatin 3 selinexor 2 lenvatinib 2 Taxes 2 Ramucirumab 2 Octreotide 2 N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide 2 Methylprednisolone 2 Erlotinib Hydrochloride 2 Chemoradiotherapy 2 zimberelimab 1 saracatinib 1 regorafenib 1 epacadostat 1 envafolimab 1 belinostat 1 avelumab 1 atezolizumab 1 amrubicin 1 alovudine 1 TP protocol 1 Radiofrequency Ablation 1 Radiation Dose Hypofractionation 1 Prednisone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02049047 2022-09-10

ONC-2010-001

Istituto Clinico Humanitas

Phase 2 Completed

Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡